Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Zeev's Turnips - No Politics -- Ignore unavailable to you. Want to Upgrade?

To: Zeev Hed who wrote (79488)	6/15/2002 6:05:01 PM
From: limtex	Respond to of 99280

ZH - I thought that politics was economics? Best, L

To: Zeev Hed who wrote (79488)	6/15/2002 6:50:57 PM
From: John R Resseger	Read Replies (1) \| Respond to of 99280

Dr. Hed's areas of patent interest include cryogenics, thermoelectrics, innovative medical devices and instruments for diagnosis and therapy, remote illumination technology, superconductors and superconducting devices, novel chemical processes and others. His motto is: "I am too stupid to know it cannot be done." So long as an assignment does not violate the laws of nature, he is willing to take a stab at it. So ya might try some of this Gefilte Fish pizza! Two unloved or followed stocks in the Medical field, both have two FDA approved devices. SMTS needs their international distributor Puritan Bennett to not be bought every 14 months! Traded 3000 shares Friday. Earnings are out next week. SMTS two products are…. The Cerebral Oximeter is the only non-invasive monitoring system commercially available in the United States that provides continuous information about changes in the blood oxygen level in the adult brain. It is easy to use and relatively inexpensive and provides medical professionals with new information to help them identify brain oxygen imbalances. This information may facilitate timely intervention, provide feedback regarding the adequacy of the selected therapy and provide medical professionals with additional assurance when they make decisions regarding the need for therapy, thereby potentially improving patient outcome and reducing the cost of care. The CorRestore System, which includes a new cardiac implant designed by CorRestore LLC, for use in cardiac repair and reconstruction, including heart surgeries called surgical ventricular restoration, or SVR. During SVR, the surgeon restores an enlarged, poorly functioning left ventricle to more normal size and function by inserting an implant, in most instances, or closing the defect directly. ALLP who needs cash soon. Just got FDA approval on Imagent a new ultrasound contrast agent that gives doctors a clearer look at a heart's main pumping chamber. Another FDA approved product RODA probably won’t amount to much. ALLP’s big Kahuna or giant squash is OxygentTM, Alliance's intravascular oxygen carrier ("blood substitute"), and will be featured in a segment of the television program "Next Frontiers: Health & Technology" scheduled to air this Sunday at 8pm and 11pm EDT on the Discovery Health Channel. . In addition, Oxygent will be discussed in an article in the June 24 issue of Newsweek magazine, which will be on the newsstands starting June 17. Alliance's David Klein, Ph.D., Senior Vice President, Research and Development, and Peter Keipert, Ph.D., Program Director, Oxygen Carriers Development, were among those interviewed for the television and magazine reports. Top management gives themselves healthy pay increases despite dwindling cash and stock price irking many common stockholders. The question DOC is, given ALLP’s cash squeeze, would going for just European approval which they had a successful Phase 3 trial make senses?